CRISPR Therapeutics prices upsized $550M convertible debt offering
Source: SeekingAlpha
2026-03-11 07:07:24 ET
More on CRISPR Therapeutics
- Is A Vertex Buyout Of Crispr Therapeutics Inevitable? Here's My Take
- Crispr Therapeutics: Very High Risk, But Even Higher Potential Reward
- CRISPR Therapeutics AG (CRSP) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript
- Cathie Wood buys the dip in gene-editing firm CRISPR Therapeutics
- CRISPR Therapeutics stock dips on $350M convertible debt offering
Read the full article on Seeking Alpha
For further details see:
CRISPR Therapeutics prices upsized $550M convertible debt offering
CRISPR Therapeutics AG
NASDAQ: CRSP
CRSP Trading
-5.35% G/L:
$50.84 Last:
4,111,575 Volume:
$52.12 Open:
CRSP Latest News
March 04, 2026 01:43:00 pm
Forget CRISPR Therapeutics: This Gene?Editing Player Already Boasts the Profits It Dreams Of
CRSP Stock Data
$4,723,079,547
91,202,323
0.18%
215
N/A
Biotechnology & Life Sciences
Healthcare
CH
Zug
